| |
|
The OmniAb platforms are licensed to companies such as Genentech, Janssen, Merck KGaA, Pfizer, Roche, and Symphogen, as well as other smaller biotech companies. OMT offers flexible terms for all targets, indications and territories with arrangements such as:
Unlimited platform access
Partners may pay annual access fees, clinical milestones and royalties or acquire an OMT spin-out.
Individual target licenses
Partners pay a single access fee and industry-standard milestones and royalties. Fees can be front- or back-loaded.
Small company license
Small companies may license antibodies generated with the OmniAb platforms for a portion of their sublicensing revenues during development and royalty on sales.
Academic license
Researchers and academic institutions may license antibodies generated with the OmniAb platforms for a portion of their sublicensing revenues.
|
|
|
|
